Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation
Figure 1
Comparison of nilotinib with imatinib. Kaplan-Meier plot of patients with Ph+ CNS relapse experiencing progressive disease leading to nilotinib discontinuation while on TKI treatment. Data for imatinib was extracted from the historical Pfeifer cohort (Pfeifer et al., [1]) and compared with data from the patients treated with nilotinib in this trial. By trend, patients treated with nilotinib had a longer time to progression, although this was not statistically significant (Chi-square-test 1.9, ).
